Pomerantz LLP is investigating Biogen Inc. for potential securities fraud following the company's announcement that its Phase 2 study on an Alzheimer's drug missed the primary dose-response endpoint, despite being described as "compelling." This news caused Biogen's stock to fall 6.43% on May 14, 2026. The investigation aims to determine if Biogen or its executives engaged in unlawful business practices. Investors affected are encouraged to contact the law firm for potential class action participation.
The 16th annual PODD (Partnership Opportunities in Drug Delivery) conference will take place on October 29-30, 2026, in Boston, gathering over 1,000 industry leaders to discuss advancements in drug delivery systems. The event features over 150 sessio...
The cutaneous lupus erythematosus (CLE) market is projected to expand at an 8% compound annual growth rate through 2036, driven by increased disease awareness, better diagnostics, and a focus on autoimmune disorders. New targeted therapies and biolog...
